MS therapy preserves cognitive function over 4 years, study shows
Mavenclad linked to better quality of life, fewer relapses
Written by |
Mavenclad showed benefits in people with RRMS. (Photo by iStock)
- Relapsing MS patients who received Mavenclad in a trial retained cognitive function over four years.
- The treatment also reduced relapses, limited disability progression, and improved overall quality of life.
- MRI results showed sustained control of inflammatory disease activity.
Most people with highly active relapsing multiple sclerosis (MS) who received the approved therapy Mavenclad (cladribine) maintained their cognitive function over four years, while experiencing improved quality of life.
That’s according to pooled results from 280 patients who completed the global Phase 4 CLARIFY-MS clinical trial (NCT03369665), where they were given Mavenclad for two years, and subsequently entered the Phase 4 CLARIFY-MS Extension study (NCT04776213), in which they were monitored for two additional years.
Data also showed that Mavenclad’s beneficial effects over the two years of treatment in terms of MS relapses and disease progression were sustained over the subsequent two years of no treatment.
The findings were described in the study, “Cognitive resilience and improvements in health-related quality of life over 4 years in people with relapsing multiple sclerosis treated with cladribine tablets: Results from the CLARIFY-MS Extension study,” published in Multiple Sclerosis and Related Disorders.
MS is marked by the immune system mistakenly attacking myelin, the protective covering surrounding nerve fibers. This disrupts communication between the brain and body, causing MS symptoms that may include fatigue, muscle weakness, and difficulties with memory and thinking.
Long-range study
Mavenclad is an oral medication approved for adults with relapsing forms of MS. It works by reducing the levels of certain immune cells involved in MS inflammation. Treatment involves two annual courses, each made up of two treatment cycles of four to five days, with no further doses routinely scheduled during years three and four.
“Existing data from … clinical trials supported by real-world studies have demonstrated the efficacy and safety of [Mavenclad] in [relapsing MS],” the researchers wrote. “However, studies evaluating the durability of [Mavenclad] treatment effect beyond the 2-year treatment period are limited.”
Data from the CLARIFY-MS study — conducted in a real-world setting after Mavenclad’s approval — showed quality of life improvements and preserved cognitive function, alongside control of relapses and disability, over the two years of treatment in nearly 500 adults with highly active relapsing MS.
In the CLARIFY-MS extension study, researchers followed CLARIFY-MS participants for two additional years to assess whether the therapy’s benefits persisted for up four years after the initial Mavenclad dose.
The analysis involved 280 patients (mean age at CLARIFY-MS’s start, 38.4; 71.8% women). Although no additional Mavenclad treatment was planned during the extension study, a few participants received further doses or switched to another DMT at the investigators’ discretion.
The main goal was to assess changes in cognitive processing speed, or how quickly the brain processes information, which was assessed using the Symbol Digit Modalities Test (SDMT).
After four years, 192 participants (68.6%) had no or minimal decline (no more than four points) on the test, reflecting no clinically meaningful worsening. Based on a four-point threshold to distinguish meaningful changes, 63.9% of patients had improved (29.6%) or stable (34.3%) SDMT scores. With an eight-point threshold, that proportion increased to 77.5%.
Other tests assessing verbal learning and visual memory also showed generally stable performance throughout follow-up.
Participants’ quality of life, measured through the MS Quality of Life-54 questionnaire that covers both physical and mental health, improved significantly after four years.
Significant score improvements were seen in both the physical and mental health subscales. More than 45% of participants with available data achieved clinically meaningful score improvements of at least five points in these subscales.
During the two-year extension, 77.5% of participants experienced no qualifying relapses, and 80.4% had no confirmed disability progression lasting at least six months. Scores on the Expanded Disability Status Scale, a validated measure of MS-related disability, remained stable over the four years.
Brain MRI findings also indicated sustained control of inflammatory disease activity. Most (72.3%) of the 83 participants with active inflammatory lesions at CLARIFY-MS’s start no longer had these lesions after four years. Conversely, nine (0.51%) of 175 participants without such lesions initially developed them by year four.
Most patients (81.1%) had no active inflammatory lesions at four years. During the two-year extension, 35.7% of all participants showed new or enlarging lesions.
Some 63.6% of participants reported at least one adverse event during the extension study, and 5.4% experienced events considered related to treatment. Two serious events — a type of blood cancer and cancer of the thyroid gland — were considered treatment-related. No deaths were reported.
Overall, the results suggest that cognitive stability and quality-of-life improvements can persist for several years after the initial Mavenclad treatment courses, although some patients continue to experience disease activity.
“This study demonstrated the sustained benefits of [Mavenclad] treatment on cognition, [health-related quality of life], relapse rate, radiological activity and disability progression, and relatively low toxicity in people with highly active [relapsing MS] for up to 4 years,” the researchers concluded.
Leave a comment
Fill in the required fields to post. Your email address will not be published.